STAT3 and breast carcinoma: Our data suggest that miR-23c may interfere with IL-6R/STAT3 signaling in breast cancer cell lines and that the upregulation of miR-23c in these cells reduces cell proliferation and migration by inhibiting IL-6R/STAT3 signaling.